Personalis (NASDAQ:PSNL) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Personalis (NASDAQ:PSNL) has received a "sell (D-)" rating from Weiss Ratings, indicating concerns about the company's financial health.
• The stock is currently trading around $8.68 with a consensus price target of $7.42 from various analysts, showcasing mixed sentiments on its future performance.
• Personalis reported a negative net margin of 113.70% and a revenue of $17.20 million for the last quarter, which fell short of analyst expectations.

Personalis (NASDAQ:PSNL - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other research firms have also weighed in on PSNL. BTIG Research set a $6.00 target price on shares of Personalis in a research note on Wednesday, August 6th. HC Wainwright reaffirmed a "buy" rating and issued a $8.50 price target on shares of Personalis in a report on Monday, September 8th. Finally, Wall Street Zen raised Personalis from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Personalis has a consensus rating of "Moderate Buy" and a consensus price target of $7.42.

Personalis Stock Performance

PSNL stock opened at $8.68 on Wednesday. The company's 50 day moving average price is $5.53 and its 200 day moving average price is $5.18. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $8.70. The firm has a market capitalization of $769.74 million, a price-to-earnings ratio of -6.78 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several large investors have recently modified their holdings of PSNL. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Personalis by 18.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after purchasing an additional 2,724 shares during the period. AIGH Capital Management LLC lifted its holdings in shares of Personalis by 4.5% during the first quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock worth $13,931,000 after purchasing an additional 169,884 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Personalis by 6.1% during the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock worth $25,231,000 after purchasing an additional 412,762 shares during the period. XTX Topco Ltd lifted its holdings in shares of Personalis by 147.0% during the first quarter. XTX Topco Ltd now owns 82,666 shares of the company's stock worth $290,000 after purchasing an additional 49,197 shares during the period. Finally, Howland Capital Management LLC lifted its holdings in shares of Personalis by 7.7% during the first quarter. Howland Capital Management LLC now owns 282,808 shares of the company's stock worth $993,000 after purchasing an additional 20,200 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.